Project Grant R01AG086433
Award Date 6/15/24
Completion Date 2/28/29
Dollars Obligated $3.9M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlestown, MA 02129, USA
Similar Awards
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,883 to Degrome Therapeutics, Inc. to develop small-molecule degraders of the amyloid precursor protein (APP) as novel therapeutics for Alzheimer's disease (AD). The project aims to optimize lead APP degrader compounds to improve their potency, solubility, and blood-brain barrier permeability, with the goal of identifying the most promising candidates for further development and evaluation...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $994,436.00 to Transchromix LLC to develop novel brain-penetrant drugs for treating Alzheimer's disease (AD). The key products and services being delivered include: Discovering a noncanonical, translation regulatory function of the histone methyltransferase G9A in AD pathogenesis using a chromatin-activity-based chemoproteomic (ChAC) approach to dissect AD heterogeneity. Deducing the mechanism...
- This federal Project Grant award of $238,500 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research conducted by the University of California, San Diego (UCSD) to develop a new phosphorodiamidate morpholino oligonucleotide (PMO) therapeutic for treating Alzheimer's disease (AD). The research aims to create a highly effective PMO that can...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $258,213 to Reelin Therapeutics, Inc. to identify the next generation of gamma-secretase modulators for the treatment of Alzheimer's disease. The research aims to develop novel lead compounds that can lower amyloid-beta 42 production, a key driver of amyloid plaque formation, while avoiding effects on other gamma-secretase substrates like Notch. Through medicinal chemistry and in vitro/in vivo...
- This Project Grant award of $751,442 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to optimize and preclinically evaluate a brain-permeable CRISPR-based therapy to edit the APOE4 gene and convert it to the benign APOE3 variant in Alzheimer's disease (AD) models. The key products and services to be delivered include: Optimizing the CRISPR delivery platform using microfluidic synthetic exosomes (SE) to enhance plasma half-life and blood-brain barrier...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
- This Project Grant award from the National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), will support the lead optimization of a therapeutic candidate for Alzheimer's disease (AD). The $349,605 award to Stress Therapeutics, Inc., a California-based biopharmaceutical company, aims to advance the development of a first-in-class treatment that can reduce hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis, a key pathogenic driver of AD...
- The National Institute on Aging (NIA), under its Aging Research program (CFDA 93.866), has awarded a $2,112,826 cooperative agreement to the University of California, San Diego (UCSD) to advance a CRISPR-based therapeutic for Alzheimer's disease (AD) towards pre-IND stage. The project aims to determine the optimal gene-editing combination to edit the APP gene, which plays a central role in AD pathogenesis, and shift the APP cleavage pathway from pathologic to physiologic. UCSD will evaluate...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,998.00 to Encue Inc., a small disadvantaged business located in Evanston, IL, to develop novel small molecule modulators of synaptic plasticity for the treatment of Alzheimer's disease (AD)-induced cognitive decline. The project aims to further develop the lead molecule JB2 as a therapeutic to reverse or delay the onset of cognitive dysfunction in AD by restoring normal expression...
- This Phase I Small Business Technology Transfer (STTR) grant from the National Institute on Aging (CFDA 93.866 - Aging Research) is supporting research by Alphamemory, LLC to target the substrate of gamma-secretase for selective amyloid reduction in Alzheimer's disease. The $252,124 award, effective September 20, 2025, will fund initial structure-activity relationship studies of a lead compound (C1) and in vivo pharmacokinetic and pharmacodynamic characterization of preclinical candidates. The...